Volume 40, Issue 5

Search all Investigational New Drugs articles

October 2022

Filter by

Volume:

Sort by

Date published:

New to old Old to new

31 articles in this issue

ZL-n-91, a specific Phosphodiesterase-4 inhibitor, suppresses the growth of triple-negative breast cancer
Longming Liang
Hansi Chen
Fanghong Li
Preclinical Studies 08 June 2022 Pages: 875 - 883
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer
Danping Yuan
Yong Tao
Zhaonan Yu
Preclinical Studies Open access 21 June 2022 Pages: 884 - 894
Mono-PEGylated thermostable Bacillus caldovelox arginase mutant (BCA-M-PEG20) induces apoptosis, autophagy, cell cycle arrest and growth inhibition in gastric cancer cells
Sai-Fung Chung
Suet-Ying Tam
Yun-Chung Leung
Research Open access 20 July 2022 Pages: 895 - 904
Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines
Risa Mia Swain
Lisett Contreras
Renato J Aguilera
Research 06 July 2022 Pages: 905 - 921
MY11 exerts antitumor effects through activation of the NF-κB/PUMA signaling pathway in breast cancer
Qun Ye
Ziwei Jiang
Lixia Pei
Research Open access 27 June 2022 Pages: 922 - 933
Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel
Minoru Horiuchi
Takehiro Uemura
Akio Niimi
Research 27 June 2022 Pages: 934 - 943
Brain pharmacokinetics and metabolism of the AMP-activated protein kinase selective inhibitor SBI-0206965, an investigational agent for the treatment of glioblastoma
Janki M. Desai
Aniruddha S. Karve
Pankaj B. Desai
Research 08 July 2022 Pages: 944 - 952
3D cell cultures, as a surrogate for animal models, enhance the diagnostic value of preclinical in vitro investigations by adding information on the tumour microenvironment: a comparative study of new dual-mode HDAC inhibitors
Sofia I. Bär
Bernhard Biersack
Rainer Schobert
Research Open access 07 July 2022 Pages: 953 - 961
Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes
Tinnabhop Santadkha
Wanwisa Skolpap
Hasan Uludağ
Research 14 July 2022 Pages: 962 - 976
Antitumor activity of mianserin (a tetracyclic antidepressant) primarily driven by the inhibition of SLC1A5-mediated glutamine transport
Zelin Duan
Zhiyun Zhou
Hongjian Zhang
Research 14 July 2022 Pages: 977 - 989
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
Todd Bauer
Byong Chul Cho
Shubham Pant
Research Open access 29 June 2022 Pages: 990 - 1000
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors
Filip Janku
Seung-Hoon Beom
Sun Young Rha
Research Open access 08 July 2022 Pages: 1001 - 1010
An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors
Yoshito Komatsu
Tsuneo Shimokawa
Kazuo Kasahara
Research Open access 06 August 2022 Pages: 1011 - 1020
Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors
Toshio Shimizu
Takako Eguchi Nakajima
David Liu
Research 06 August 2022 Pages: 1021 - 1031
Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies
Yu Sunakawa
Keishiro Takahashi
Nobuyuki Yamamoto
Research Open access 30 June 2022 Pages: 1032 - 1041
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
Xiaofei Zhou
Ulka Vaishampayan
Neeraj Gupta
Research Open access 06 August 2022 Pages: 1042 - 1050
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
Stergios J. Moschos
Shahneen Sandhu
Keith T. Flaherty
PHASE I STUDIES Open access 30 May 2022 Pages: 1051 - 1065
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
Hisao Imai
Yoshiaki Nagai
Hiroshi Kagamu
Research Open access 24 June 2022 Pages: 1066 - 1079
Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial
M Mego
D Svetlovska
M Chovanec
Research 28 June 2022 Pages: 1080 - 1086
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors
Nabil Adra
David J. Vaughn
Darren R. Feldman
Research 27 June 2022 Pages: 1087 - 1094
Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
Tiandong Kong
Lu Chen
Danna Liu
Research 05 July 2022 Pages: 1095 - 1105
Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study
Sae Ohwada
Akiko Todaka
Kentaro Yamazaki
SHORT REPORT 28 July 2022 Pages: 1106 - 1116
Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study
Yu Xu
Rong Guo
Jie Jin
Research Open access 14 July 2022 Pages: 1117 - 1124
Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma
Peng Yuan
Jinhua Song
Baoan Chen
Short Report 06 July 2022 Pages: 1125 - 1132
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046
Matteo Repetto
Edoardo Crimini
Giuseppe Curigliano
Short Report 25 May 2022 Pages: 1133 - 1136
Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report
Kei Kunimasa
Naotoshi Sugimoto
Kazumi Nishino
Case Report 03 June 2022 Pages: 1137 - 1140
Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma
Juanyan Liao
Hui Guan
Shuang Zhang
Case Report Open access 21 June 2022 Pages: 1141 - 1145
The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy: a predicted regression model
Haomin Lin
Bin Luo
Song Su
Review 20 June 2022 Pages: 1146 - 1152
Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome
Yang He
Weijin Fang
Chunjiang Wang
Research 22 July 2022 Pages: 1153 - 1159
Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion
Xinyi Lin
Xiaojuan Yang
Mei He
Letters to the Editor 24 May 2022 Pages: 1160 - 1163
Author Correction: The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients
Chao Li
Mengdong Zhang
Xiaodong Zhang
Author Correction Open access 05 July 2022 Pages: 1164 - 1164

Volume 40, Issue 5

ZL-n-91, a specific Phosphodiesterase-4 inhibitor, suppresses the growth of triple-negative breast cancer

A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer

Mono-PEGylated thermostable Bacillus caldovelox arginase mutant (BCA-M-PEG20) induces apoptosis, autophagy, cell cycle arrest and growth inhibition in gastric cancer cells

Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines

MY11 exerts antitumor effects through activation of the NF-κB/PUMA signaling pathway in breast cancer

Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel

Brain pharmacokinetics and metabolism of the AMP-activated protein kinase selective inhibitor SBI-0206965, an investigational agent for the treatment of glioblastoma

3D cell cultures, as a surrogate for animal models, enhance the diagnostic value of preclinical in vitro investigations by adding information on the tumour microenvironment: a comparative study of new dual-mode HDAC inhibitors

Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes

Antitumor activity of mianserin (a tetracyclic antidepressant) primarily driven by the inhibition of SLC1A5-mediated glutamine transport

First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors

First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors

An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors

Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors

Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer

Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial

A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors

Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study

Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study

Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study

Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma

The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046

Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report

Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma

The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy: a predicted regression model

Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome

Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion

Author Correction: The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients

Navigation